US Stock MarketDetailed Quotes
XFOR X4 Pharmaceuticals
- 0.655
- -0.005-0.76%
Close Sep 27 16:00 ET
- 0.670
- +0.015+2.27%
Post 18:45 ET
110.37MMarket Cap5.04P/E (TTM)
0.684High0.650Low687.33KVolume0.680Open0.660Pre Close453.01KTurnover0.54%Turnover RatioLossP/E (Static)168.50MShares1.60052wk High1.17P/B84.13MFloat Cap0.53152wk Low--Dividend TTM128.44MShs Float23.930Historical High--Div YieldTTM5.09%Amplitude0.531Historical Low0.659Avg Price1Lot Size
X4 Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -41.32%-30.28M | -26.72%-33.6M | -25.17%-96.51M | -45.33%-27.75M | -7.88%-20.83M | -15.97%-21.43M | -31.06%-26.51M | -8.74%-77.1M | -0.21%-19.09M | -35.85%-19.31M |
| Net income from continuing operations | 263.04%90.83M | -115.51%-51.77M | -7.78%-101.17M | 34.27%-19.13M | 89.32%-2.31M | -162.64%-55.71M | -9.36%-24.02M | -5.83%-93.87M | 3.65%-29.1M | -6.99%-21.59M |
| Operating gains losses | -519.34%-125.22M | 352.90%13.76M | -345.54%-7.07M | ---6.33M | ---25.16M | --29.86M | ---5.44M | 687.16%2.88M | ---- | ---- |
| Depreciation and amortization | 53.97%194K | -51.18%62K | -18.32%419K | -50.00%62K | -16.13%104K | -4.55%126K | -4.51%127K | 2.81%513K | -6.06%124K | -6.06%124K |
| Other non cash items | -29.04%435K | -6.44%523K | -6.44%2.28M | 11.08%471K | -45.87%636K | 55.98%613K | 25.90%559K | -2.01%2.44M | -31.06%424K | 44.00%1.18M |
| Change In working capital | -32.21%1.05M | 239.29%2.09M | -94.00%344K | -197.86%-5.36M | 2,823.08%3.54M | 123.73%1.55M | 305.33%616K | 482.91%5.74M | 512.90%5.48M | -103.71%-130K |
| -Change in prepaid assets | 120.93%336K | -49.04%1.06M | -124.59%-1.37M | -138.15%-1.83M | 96.98%-20K | -97.66%-1.61M | 27.62%2.08M | 65.24%-610K | 55.89%-768K | -135.38%-663K |
| -Change in payables and accrued expense | -47.80%1.79M | 204.11%1.27M | -60.68%2.84M | -150.52%-3.24M | 397.17%3.87M | 96.62%3.43M | 28.23%-1.22M | 612.82%7.23M | 900.63%6.4M | -57.23%778K |
| -Change in other current assets | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| -Change in other current liabilities | 10.87%-246K | 4.00%-240K | -27.89%-1.13M | -82.61%-294K | -25.71%-308K | -15.00%-276K | -5.93%-250K | -26.36%-882K | 28.44%-161K | -26.94%-245K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -41.32%-30.28M | -26.72%-33.6M | -25.17%-96.51M | -45.33%-27.75M | -7.88%-20.83M | -15.97%-21.43M | -31.06%-26.51M | -8.74%-77.1M | -0.21%-19.09M | -35.85%-19.31M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 2,083.25%96.86M | -59,033.33%-5.32M | -14,349.51%-14.88M | -14,114.71%-4.83M | -57,200.00%-5.16M | -12,752.63%-4.88M | 59.09%-9K | 83.25%-103K | -161.54%-34K | 55.00%-9K |
| Net PPE purchase and sale | -1,575.00%-134K | -555.56%-59K | 41.75%-60K | -2.94%-35K | 11.11%-8K | 78.95%-8K | 59.09%-9K | 83.25%-103K | -161.54%-34K | 55.00%-9K |
| Net investment purchase and sale | 79.41%-1M | ---5.26M | ---14.82M | ---4.8M | ---5.15M | ---4.88M | --0 | --0 | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 2,083.25%96.86M | -59,033.33%-5.32M | -14,349.51%-14.88M | -14,114.71%-4.83M | -57,200.00%-5.16M | -12,752.63%-4.88M | 59.09%-9K | 83.25%-103K | -161.54%-34K | 55.00%-9K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -70.93%20.16M | 0 | -24.49%88.52M | -99.84%97K | -59.20%21.21M | 20,082.13%69.34M | -142.86%-2.12M | 57.90%117.23M | 146.82%60.64M | 1,270.13%51.98M |
| Net issuance payments of debt | 5,149.34%20M | --0 | 2,670.57%20.44M | --0 | 4,851.25%21.74M | 217.23%381K | -84.93%-1.68M | ---795K | --0 | --439K |
| Net common stock issuance | --0 | --0 | -51.07%60M | --0 | -100.52%-283K | 276,122.73%60.73M | -107.54%-443K | 65.75%122.63M | 153.44%62.01M | 1,332.96%54.77M |
| Proceeds from stock option exercised by employees | ---- | ---- | 4,088.46%8.71M | -78.82%728K | ---629K | ---- | ---- | -20.00%208K | 3,237.86%3.44M | ---- |
| Net other financing activities | ---- | ---- | 86.89%-631K | ---- | ---- | ---- | ---- | ---4.81M | ---4.8M | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -70.93%20.16M | --0 | -24.49%88.52M | -99.84%97K | -59.20%21.21M | 20,082.13%69.34M | -142.86%-2.12M | 57.90%117.23M | 146.82%60.64M | 1,270.13%51.98M |
| Net cash flow | ||||||||||
| Beginning cash position | -35.12%61.27M | -18.52%100.25M | 48.03%123.03M | 63.41%132.6M | 182.35%137.46M | 39.40%94.43M | 48.03%123.03M | 2.98%83.11M | 4.41%81.15M | -49.55%48.68M |
| Current changes in cash | 101.59%86.74M | -35.87%-38.92M | -157.16%-22.88M | -178.24%-32.48M | -114.63%-4.78M | 328.16%43.03M | -87.28%-28.65M | 1,368.81%40.03M | 654.31%41.52M | 274.92%32.66M |
| Effect of exchange rate changes | -200.00%-18K | -218.00%-59K | 194.29%99K | -65.01%127K | 63.45%-72K | 97.03%-6K | 172.46%50K | 67.08%-105K | 412.93%363K | -97.00%-197K |
| End cash Position | 7.67%148M | -35.12%61.27M | -18.52%100.25M | -18.52%100.25M | 63.41%132.6M | 182.35%137.46M | 39.40%94.43M | 48.03%123.03M | 48.03%123.03M | 4.41%81.15M |
| Free cash flow | -74.55%-37.41M | -26.90%-33.66M | -25.09%-96.57M | -45.25%-27.78M | -7.87%-20.84M | -15.78%-21.43M | -30.96%-26.52M | -7.95%-77.21M | -0.32%-19.13M | -35.72%-19.32M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data